Galectin Therapeutics Q2 EPS $(0.14) Misses $(0.09) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.09) by 55.56 percent. This is a 16.67 percent decrease over losses of $(0.12) per
Galectin lost more money per share than experts predicted, and their losses are also getting bigger over time. When a company's losses grow and miss expectations, it can make investors worried about how well the business is doing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.